In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced dosing has been completed in ...

The investment firm said it believes TRACER alone should be a valuable asset, noting “initial novel AAV capsid candidates ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

Objective Adeno-associated virus (AAV) is a defective mono-stranded DNA virus, endemic in human population (35%–80%). Recurrent clonal AAV2 insertions are ...

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the ...